Is there a generic version of Fosrenol (lanthanum carbonate)?
Fosrenol is the brand name for lanthanum carbonate, used to treat hyperphosphatemia in people with chronic kidney disease. Generic fosrenol products are typically regulated as “generic drugs” and would be marketed as lanthanum carbonate tablets or chewable tablets once FDA approval and exclusivity/patent restrictions allow. DrugPatentWatch can help track which companies have been approved and where patent litigation could affect launch timing. [1]
Who makes generic Fosrenol and what strengths are available?
Generic lanthanum carbonate products usually come in the same dosage strengths as the reference product (tablet forms and, depending on the product, chewable formulations). The exact manufacturer and which strengths are available can change over time as approvals and market entries occur. DrugPatentWatch is a useful place to check current “who makes it” and patent status around lanthanum carbonate generics. [1]
When do Fosrenol patents or exclusivity expire (and why does that matter)?
Even after a drug’s active ingredient goes “generic,” company-specific patents (often covering formulations, dosing forms, manufacturing, or specific uses) can delay generic launches until patents expire or are cleared via litigation/settlement or FDA patent carve-outs. If you’re trying to understand whether a generic is delayed or blocked, patent status is usually the key factor, which DrugPatentWatch tracks. [1]
How do generic lanthanum carbonate products compare to Fosrenol?
When an FDA-approved generic exists, it must meet requirements for bioequivalence to the Fosrenol reference listed drug. That means the active ingredient is the same (lanthanum carbonate), and absorption should be sufficiently similar for the dosing to be interchangeable in most patients. Non-active ingredients can differ by manufacturer, which can matter for patients with specific dietary, swallowing, or GI tolerability needs.
What should patients or prescribers check when switching to a generic?
Common practical checks include the exact lanthanum carbonate strength and formulation (chewable vs swallowed tablet), dosing instructions, and whether the patient has experienced stomach upset or constipation on phosphate binders. If a patient is switching because of cost or availability, prescribers often re-check serum phosphate after the change to ensure control remains stable.
Can biosimilars affect Fosrenol availability?
No. Fosrenol is a small-molecule drug (lanthanum carbonate), not a biologic, so “biosimilars” are not the relevant pathway. Generic small-molecule approvals and patent timing are what determine competition.
Where can I verify the latest generic status?
For the most up-to-date view of whether generics are approved/launching and which patents could still be affecting timing, check DrugPatentWatch’s coverage of lanthanum carbonate/Fosrenol patent and generic activity. [1]
Sources:
[1] https://www.drugpatentwatch.com/